Cargando…

Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms

Chronic inflammation is considered a major driving force for clonal expansion and evolution in the Philadelphia-negative myeloproliferative neoplasms, which include essential thrombocythemia, polycythemia vera and primary myelofibrosis (MPNs). One of the key mutation drivers is the JAK2V617F mutatio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Skov, Vibe, Thomassen, Mads, Kjær, Lasse, Ellervik, Christina, Larsen, Morten Kranker, Knudsen, Trine Alma, Kruse, Torben A., Hasselbalch, Hans C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9246201/ https://www.ncbi.nlm.nih.gov/pubmed/35771847 http://dx.doi.org/10.1371/journal.pone.0270669

Ejemplares similares

Recombinant Interferon-β in the Treatment of Polycythemia Vera and Related Neoplasms: Rationales and Perspectives
por: Hasselbalch, Hans, et al.
Publicado: (2022)

Safety and efficacy of combination therapy of interferon‐α2 and ruxolitinib in polycythemia vera and myelofibrosis
por: Mikkelsen, Stine Ulrik, et al.
Publicado: (2018)

The gut microbiota in patients with polycythemia vera is distinct from that of healthy controls and varies by treatment
por: Eickhardt-Dalbøge, Christina Schjellerup, et al.
Publicado: (2022)

Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study
por: Sørensen, Anders Lindholm, et al.
Publicado: (2020)

Data‐driven analysis of JAK2V617F kinetics during interferon‐alpha2 treatment of patients with polycythemia vera and related neoplasms
por: Pedersen, Rasmus K., et al.
Publicado: (2020)

Whole Blood Transcriptional Profiling Reveals Deregulation of Oxidative and Antioxidative Defence Genes in Myelofibrosis and Related Neoplasms. Potential Implications of Downregulation of Nrf2 for Genomic Instability and Disease Progression
por: Hasselbalch, Hans Carl, et al.
Publicado: (2014)

Revisiting Circulating Extracellular Matrix Fragments as Disease Markers in Myelofibrosis and Related Neoplasms
por: Hasselbalch, Hans Carl, et al.
Publicado: (2023)

JAK2V617F mutation is highly prevalent in patients with ischemic stroke: a case-control study
por: Kristiansen, Marie Hvelplund, et al.
Publicado: (2023)

A novel integrated biomarker index for the assessment of hematological responses in MPNs during treatment with hydroxyurea and interferon‐alpha2
por: Dam, Marc J. B., et al.
Publicado: (2022)

Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment
por: Kjær, Lasse, et al.
Publicado: (2016)

Myeloproliferative blood cancers as a human neuroinflammation model for development of Alzheimer’s disease: evidences and perspectives
por: Hasselbalch, Hans C., et al.
Publicado: (2020)

Serum levels of IL-4, IL-13 and IL-33 in patients with age-related macular degeneration and myeloproliferative neoplasms
por: Gotfredsen, Kathrine, et al.
Publicado: (2023)

Mathematical modelling as a proof of concept for MPNs as a human inflammation model for cancer development
por: Andersen, Morten, et al.
Publicado: (2017)

Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?
por: Hasselbalch, Hans Carl, et al.
Publicado: (2018)

Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis
por: Kjær, Lasse, et al.
Publicado: (2023)

Retinal drusen in patients with chronic myeloproliferative blood cancers are associated with an increased proportion of senescent T cells and signs of an aging immune system
por: Liisborg, Charlotte, et al.
Publicado: (2021)

Patients with MPNs and retinal drusen show signs of complement system dysregulation and a high degree of chronic low-grade inflammation
por: Liisborg, Charlotte, et al.
Publicado: (2021)

Lower CXCR3 expression in both patients with neovascular AMD and advanced stages of chronic myeloproliferative blood cancers
por: Liisborg, Charlotte, et al.
Publicado: (2022)

Elevated levels of oxidized nucleosides in individuals with the JAK2V617F mutation from a general population study
por: Sørensen, Anders L., et al.
Publicado: (2021)

Pronounced gut microbiota signatures in patients with JAK2V617F-positive essential thrombocythemia
por: Eickhardt-Dalbøge, Christina Schjellerup, et al.
Publicado: (2023)

Transcriptional Profiling of Whole Blood Identifies a Unique 5-Gene Signature for Myelofibrosis and Imminent Myelofibrosis Transformation
por: Hasselbalch, Hans Carl, et al.
Publicado: (2014)

Ruxolitinib in Myelofibrosis and Polycythemia Vera
por: Wolfe, Leah
Publicado: (2016)

Thromboembolic events in polycythemia vera
por: Griesshammer, Martin, et al.
Publicado: (2019)

Genetic Background of Polycythemia Vera
por: Regimbeau, Mathilde, et al.
Publicado: (2022)

Differential cytokine network profile in polycythemia vera and secondary polycythemia
por: Cacemiro, Maira da Costa, et al.
Publicado: (2020)

Patients With Myeloproliferative Neoplasms Harbor High Frequencies of CD8 T Cell-Platelet Aggregates Associated With T Cell Suppression
por: Carnaz Simões, Ana Micaela, et al.
Publicado: (2022)

Lemierre’s Syndrome in an Elderly Female Patient with Polycythemia Vera: Does Polycythemia Vera Predispose to Lemierre’s Syndrome?
por: Kundal, Sanchit V., et al.
Publicado: (2021)

Corrigendum: Patients with myeloproliferative neoplasms harbor high frequencies of CD8 T cell-platelet aggregates associated with T cell suppression
por: Simões, Ana Micaela Carnaz, et al.
Publicado: (2022)

Polycythemia vera presenting with bilateral papilledema
por: Nithyanandam, Suneetha
Publicado: (2009)

Electrocardiographic Findings in Patients with Polycythemia Vera
por: Kayrak, Mehmet, et al.
Publicado: (2011)

Hypercalcemia in a Patient with Polycythemia Vera
por: Bae, Eun Hui, et al.
Publicado: (2012)

JAK2 Negative Polycythemia Vera
por: Geetha, J P, et al.
Publicado: (2010)

Chorea disclosing a polycythemia vera
por: Liu, Guidong, et al.
Publicado: (2014)

An oncolytic parasite to treat polycythemia vera
por: Rizvi, Syeda Taliya, et al.
Publicado: (2015)

Bilateral adrenal hemorrhage in polycythemia vera
por: Bhandari, Shruti, et al.
Publicado: (2016)

Therapy of polycythemia vera: is it time to change?
por: Passamonti, Francesco, et al.
Publicado: (2017)

Polycythemia vera treatment algorithm 2018
por: Tefferi, Ayalew, et al.
Publicado: (2018)

When hemolysis masks polycythemia vera
por: Derrieux, Coralie, et al.
Publicado: (2019)

Takotsubo Cardiomyopathy Associated with Polycythemia Vera
por: Basnet, Sijan, et al.
Publicado: (2018)

Is there a gender effect in polycythemia vera?
por: Palandri, Francesca, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_dbemso072kpthd0lm2ud5juqg7